| Literature DB >> 28820474 |
Awais Wahab1, Kuo Gao2, Caixia Jia3, Feilong Zhang4, Guihua Tian5,6, Ghulam Murtaza7,8,9, Jianxin Chen10.
Abstract
Resveratrol could be beneficial to health and provides protection against a wide array of pathologies and age-associated problems, as evident from preclinical studies. However, a comparison of animal and human studies reveals that this dietary polyphenol cannot protect against metabolic diseases and their associated complications. The clinical outcomes are affected by many factors such as sample size. This article not only presents a comprehensive review of the current advances concerning the dose, the extent of absorption, interaction and toxicity of resveratrol in human studies, but also describes its therapeutic effects against several chronic diseases such as diabetes mellitus, obesity, cardiovascular diseases, cancer and aging and the related diseases.Entities:
Keywords: absorption; aging; cancer; cardiovascular diseases; clinical studies; diabetes mellitus; obesity; pre-clinical studies; toxicity
Mesh:
Substances:
Year: 2017 PMID: 28820474 PMCID: PMC6152193 DOI: 10.3390/molecules22081329
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Molecular targets of resveratrol retrieved through the STITCH 5.0 database. Note: SIRT1—sirtuin 1; ESR1—estrogen receptor 1; PPARG—peroxisome proliferator—activated receptor gamma; NOS3—nitric oxide synthase 3; SIRT5—sirtuin 5; PTGS2—prostaglandin—endoperoxide synthase 2; PTGS1—prostaglandin-endoperoxide synthase 1; AKT1—v-akt murine thymoma viral oncogene homolog 1; SIRT3—sirtuin 3; TP53—tumor protein p53; PTEN—phosphatase and tensin homolog; NQO2—NAD(P)H dehydrogenase, quinone 2; NAMPT—nicotinamide phosphoribosyltransferase; IGF1—insulin-like growth factor 1; FOXO3—forkhead box O3; FOXO1—forkhead box O1; HMOX1—heme oxygenase (decycling) 1; PPARA—peroxisome proliferator-activated receptor alpha; NFE2L2—nuclear factor (erythroid-derived 2)-like 2; CYP1A1—cytochrome P450, family 1, subfamily A, polypeptide 1.
Figure 2Short review of the resveratrol effects in clinical trials in patients suffering from type 2 diabetes mellitus, obesity, cardiovascular diseases (CVD) disease, skin disorders or cancer.
Clinical findings on diseased participants treated with resveratrol.
| Disease | No. of Treated Subjects (Males, Females or Both) | Dose of Resveratrol | Duration of Treatment in Days | Important Findings | Reference |
|---|---|---|---|---|---|
| T2DM | 57 (Both) | 250 mg | 120 | Ameliorated profiles of lipids (total cholesterol by 7.8%), total proteins (by 4.36%) and hemoglobin A1c (by 3.4%) | [ |
| T2DM | 19 (Males) | 5 mg | 30 | Reduced blood glucose levels and ameliorated insulin resistance | [ |
| T2DM | 35 (Males) | 8 mg | 365 | Down-regulation of various cytokines including CCL3 and TNF | [ |
| Obesity | 8 (Both) | 1000–2000 mg | 14 | Non-significant effect on lipid profile but lowered synthesis of apoB-48 and apoB-100 | [ |
| Obesity | 74 (Males) | 500 mg | 105 | Increased bone density | [ |
| Obesity | 19 (Both) | 30, 90 or 270 mg | 21 | Significantly elevated FMD | [ |
| Impaired glucose tolerance (Obesity) | 10 (Both) | 1000–2000 mg | 28 | Ameliorated insulin sensitivity | [ |
| Metabolic syndrome (obesity) | 24 (Both) | 500 mg | 90 | Significantly reduced weight, BMI, fat mass, and weight, Significant effect on insulin sensitivity. | [ |
| Non-alcoholic fatty liver disease | 20 (Males) | 3000 mg | 56 | Non-significant effect on insulin function and fat distribution | [ |
| Non-alcoholic fatty liver disease | 49 (Both) | 500 mg | 84 | Significant decline in hepatic inflammatory markers | [ |
| Colorectal cancer and hepatic metastases | 9 (Both) | 5000 g | 21 | Excellent distribution of RSV in body | [ |
| Colorectal cancer | 20 (Both) | 500 mg | 8 | Reduced proliferation in in cancerous tissue | [ |
| Colon cancer | 8 (Both) | 80 mg | 14 | No effect on Wnt signaling in cancerous mucosa | [ |
| Breast cancer | 31 (Females) | 5 or 50 mg | 84 | Modified methylation of RASSF-1 (an indicator of breast cancer) | [ |
| Angina pectoris | 116 (Both) | 20 mg | 60 | Significant decline in hs-CRP | [ |
| Coronary heart disease | 75 (Both) | 8 mg | 365 | Elevated levels of adiponectin and decrease in PAI-1 | [ |
| Myocardial infarction | 40 (Both) | 10 mg | 120 | Ameliorated functioning of endothelium and left ventricle as well as reduced level of LDL | [ |
Clinical investigations on healthy subjects (participants receiving no other medicine) supplemented with resveratrol.
| Aim (To Study the Effect of Resveratrol) | No. of Treated Subjects (Males, Females or Both) | Dose of Resveratrol | Duration of Treatment in Days | Important Findings | Reference |
|---|---|---|---|---|---|
| On metabolic profile | 32 (Both) | 300 or 1000 mg | 84 | Suppressed levels of fasting glucose (by 1.67 ± 1.51 mg/dL at 300 mg dose) and bilirubin | [ |
| On metabolic profile | 24 (Males) | 500 mg | 28 | Non-significant change in the markers of obesity | [ |
| On metabolic profile | 16 (Males) | 150 mg | 28 | Non-significant effect on aerobic or anaerobic capacity | [ |
| On metabolic profile | 11 (Males) | 150 mg | 30 | Enhanced oxidative phosphorylation and reduced postprandial energy expenditure and adipose tissue lipolysis | [ |
| On metabolic profile and insulin sensitivity | 29 (Females) | 75 mg | 84 | Non-significant effect on metabolic rate or the insulin sensitivity | [ |
| On energy expenditure and substrate metabolism | 18 (Both) | 200 mg | 3 | Significantly improved fasting and postprandial energy expenditure | [ |
| On postprandial incretin hormone levels | 10 (Males) | 150 mg | 30 | Significant suppression of postprandial glucagon response | [ |
| On adipose tissue morphology | 11 (Males) | 150 mg | 30 | Significantly reduced adipocyte size as well as ameliorated insulin sensitivity | [ |
| On markers of oxidative and inflammatory stress. | 20 (Both) | 40 mg | 42 | Diminished levels of oxidative stress and inflammation biomarkers | [ |
| On markers of oxidative and inflammatory stress. | 10 (Both) | 100 mg | Single dose | Suppressed the increase in oxidative stress, lipopolysaccharide and LBP concentrations | [ |
| On markers of oxidative stress in obese patients. | 32 (Both) | 150 mg | Single dose | Significantly higher antioxidant effect of RSV triphosphate (RTP) and grape extract than RSV | [ |
| On inflammation and oxidative stress markers in smokers. | 50 (Both) | 500 mg | 90 | Diminished levels of C-reactive protein and triglycerides, and increased total antioxidant levels | [ |
| On human mononuclear cells upon bacterial stimulation. | 10 (Males) | 5000 mg | Single dose | Increase in TNF-levels while IL-10 levels were decreased. | [ |
| On cerebral blood flow and cognitive performance | 9 (Males) | 250 mg and 500 mg | Single dose | Increased cerebral blood flow | [ |
| On flow-mediated dilation (FMD) and cognitive performance. | 28 (Both) | 75 mg | 42 | No adverse side effects | [ |
| On flow-mediated dilation (FMD) and cognitive performance | 6 (Males) | 250 mg | Single dose | Significant increase in FMD | [ |
| On cognitive performance | 46 (Both) | 200 mg | 182 | Significantly improved memory retention | [ |
| On endothelial response and vascular markers. | 41 (Both) | 400 mg | 30 | Protection against atherosclerosis | [ |
| On systemic sex hormone levels | 40 (Females) | 500 mg | 84 | Significant increase in sex-hormone binding globulin | [ |
| Of administered form on bioavailability | 15 (Both) | 40 mg | Single dose | Ameliorated absorption in dry powder form | [ |
| Of gut microbiota on metabolism of resveratrol | 22 (Both) | 0.5 mg/kg | Single dose | Variable metabolism of resveratrol among individuals | [ |